Eli Lilly’s 151-Patient LIBRETTO-432 Trial Cuts Lung Cancer Recurrence Risk
Dana Unconstrained Equity ETF holds 7.58% of Eli Lilly, whose Phase 3 LIBRETTO-432 trial for selpercatinib showed a significant event-free survival improvement in 151 early-stage RET fusion-positive NSCLC patients. Safety profile was consistent with prior studies and detailed results will be presented at an upcoming medical congress.
1. Positive Phase 3 LIBRETTO-432 Outcomes
The LIBRETTO-432 trial enrolled 151 patients with early-stage RET fusion-positive non-small cell lung cancer and showed a highly statistically significant reduction in disease recurrence or death with selpercatinib compared to placebo. This marks the first randomized Phase 3 evaluation of a selective RET kinase inhibitor in the adjuvant setting.
2. Safety Profile and Upcoming Data
Selpercatinib’s overall safety profile in this trial remained consistent with earlier studies, with no new adverse signals identified. Detailed efficacy and safety data are expected to be presented at an upcoming medical congress.
3. Implications for Dana Unconstrained Equity ETF
Dana Unconstrained Equity ETF allocates 7.58% of its portfolio to Eli Lilly, making the trial outcome a material catalyst for the ETF’s performance. Positive trial news could drive fund inflows and benefit DUNK’s top-heavy exposure to pharmaceutical equities.